A fresh look at pulmonary hypertension: practical takeaways for patient management

Dr John Coghlan going to share his insights with us on evidence - based treatment decisions in pulmonary arterial hypertension.

Facing anticoagulation dilemmas in venous thromboembolism

Professor Ingrid Pabinger held a presentation on extended anticoagulation in venous thromboembolism at the recent ESC Congress in Barcelona. We asked her to share the most important conclusions with us.

Influenza Vaccine Among Patients with Acute Coronary Syndromes: the VIP-ACS trial

Professor Remo Furtado had an important presentation on the Influenza Vaccine among patients with Acute Coronary Syndromes at this year’s ESC Congress. He is going to share his insights with us on the topic.

The importance of optimal RAASi therapy in heart failure

Professor Dan Atar had an important presentation on the importance of optimal RAASi therapy in heart failure at this year’s ESC Congress. He is going to share his insights with us on the topic.

Chronic coronary syndrome: re-thinking treatment management and outcome priorities

Professor Athanasios J. Manolis chaired a very eye-opening session on how to improve care in patients with chronic coronry syndrome at this years ESC Congress. We asked him to share his insights with us on the topic.

Dual antiplatelet therapy in practice

Professor Roxana Mehran chaired a very special Guidelines in Practice session at this year’s ESC Congress on dual antiplatelet therapy. We asked her to share the most important conclusions with us.

Guidelines in Practice: management of dyslipidaemias in the elderly

Professor Ricardo Asteggiano chaired a guideline is practice session on the management of dyslipidaemias in the elderly at this years ESC Congress. We asked him to share the most important conclusions with us.

2022 ESC-ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Professor Marion Delcroix co-chareid the session presenting the 2022 ESC-ERS guideline for the diagnosis and treatment of pulmonary hypertension at this year’s ESC congress. We asked her to highlighting the most important points of the new recommendations. The complete guideline can be found on the ESC website here.

Guidelines in Practice: dual antiplatelet therapy (DAPT)

Professor Robert Storey  co-chaired a very interesting Guidelines in Practice session on dual antiplatelet therapy at this year’s ESC Congress.  The session was started with a case presentation of a patient undergoing complex PCI for NSTE-ACS with high risk both for bleeding and trombotic complications. 

Cardiorenal benefits of finerenone: protecting the heart and kidneys

Professor George Bakris chaired a very interesting session at the recent ESC Congress on the Cardiorenal benefits of finerenone, which is indicated for the treatment of chronic kidney disease associated with type 2 diabetes. We asked him for sharing his insights ont he topic.

Getting to LDL-C goals and staying there long-term

Professor Mamas Mamas chaired a very interesting interactive session at this years ESC Congress in Barcelona. We asked him to share his insights with us on the topic.

Diagnosis and management of primary aldosteronism

Professor Paolo Mulatero co-chaired a Meet the Expert session about the novelties diagnosis and management of primary aldosteronism at the recent ESH 2022.

Special forms of hypertension, optomized prevention and hypertension epidemiology: Novelties from ESH 2022

Professor Gianfranco Parati took part in many interesting sessions during the recent European Society of Hypertension. We asked to share his insight on the novelties from ESH 2022 with the audience.

Adherence to antihypertensive treatment in patients with CKD: a barrier to optimal renoprotection

We asked Professor Michel Burnier about the adherence to antihypertensive treatment in patients with CKD, what he presented at the ESH Working Group on Hypertension and Kidney during the recent European Socity of Hypertension congress in Athens.

Implementation of the 2019 lipid guidelines: where are we now?

Professor Alberico L. Catapano spoke about the European Atherosclerosis Society annual meeting, the novelties presented there, the ESC/EAS joint session discussing the new dyslipidemia guideline.

Diagnosis and management of non-adherence in hypertension treatment

Professor Jan Václavík held a lecture at the recent European Society of Hypertension 2022 Congress about the diagnosis of non-adherence in antihypertensive treatment.

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

HOPE 4 - Impact on cardiovascular risk of a community based multifaceted intervention in individuals with hypertension in 2 middle income countries: The Heart Outcomes Prevention and Evaluation 4 study

SYNTAXES: Ten-Year Survival after Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention: The SYNTAX Extended Survival study

MITRA-FR - 2 years follow-Up of the MITRA-FR study a randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation

DAPA HF The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial

CONDI-2/ERIC-PPCI Effect of remote ischemic conditioning on clinical outcomes in patients with Stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention